Glycyx MOR

Glycyx Therapeutics (operating as Glycyx MOR, Inc.) is a clinical-stage biotechnology company focused on addressing opioid-induced immunotherapy failure (OIIF) in cancer treatment. The company's lead candidate, axelopran, is a peripherally restricted mu-opioid receptor (MOR) antagonist designed to block the immunosuppressive effects of opioids without compromising pain relief. By restoring T-cell infiltration and reducing immune exhaustion in the tumor microenvironment, axelopran aims to enhance the efficacy of immune checkpoint inhibitors in patients with solid tumors. Glycyx is currently advancing axelopran into Phase 2 clinical trials for indications such as head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and melanoma. The company is supported by NIH SBIR funding and maintains strategic collaborations with academic institutions like the UPMC Hillman Cancer Center.